Syndax Pharmaceuticals - SNDX Stock Forecast, Price & News

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD). The company is also developing Entinostat. It also has collaborative research and development agreement with National Cancer Institute; a clinical trial agreement with Eastern Cooperative Oncology Group; and a license agreement with Kyowa Hakko Kirin Co., Ltd. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.Massachusetts.

Analysts Set New Price Targets

Several equities analysts recently commented on SNDX shares. StockNews.com lowered shares of Syndax Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Friday, May 13th. The Goldman Sachs Group dropped their price objective on shares of Syndax Pharmaceuticals from $40.00 to $35.00 and set a "buy" rating for the company in a research report on Tuesday, August 9th. B. Riley reissued a "buy" rating and issued a $31.00 price objective on shares of Syndax Pharmaceuticals in a research report on Thursday, July 28th. Finally, Robert W. Baird increased their price objective on shares of Syndax Pharmaceuticals to $32.00 in a research report on Monday. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Hold" and an average target price of $30.00.

Syndax Pharmaceuticals Stock Down 0.4 %

SNDX traded down $0.11 during trading hours on Tuesday, reaching $24.63. 5,304 shares of the stock traded hands, compared to its average volume of 688,819. The firm's fifty day simple moving average is $19.65 and its two-hundred day simple moving average is $17.53. The company has a market cap of $1.39 billion, a price-to-earnings ratio of 154.63 and a beta of 1.32. Syndax Pharmaceuticals has a fifty-two week low of $13.27 and a fifty-two week high of $25.71. The company has a debt-to-equity ratio of 0.04, a current ratio of 12.69 and a quick ratio of 12.69.

Insider Activity at Syndax Pharmaceuticals

In related news, CEO Michael A. Metzger sold 31,602 shares of the firm's stock in a transaction on Monday, July 25th. The shares were sold at an average price of $21.06, for a total transaction of $665,538.12. Following the completion of the sale, the chief executive officer now directly owns 17,659 shares of the company's stock, valued at approximately $371,898.54. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. In other Syndax Pharmaceuticals news, CEO Michael A. Metzger sold 31,602 shares of the stock in a transaction on Monday, July 25th. The shares were sold at an average price of $21.06, for a total transaction of $665,538.12. Following the transaction, the chief executive officer now directly owns 17,659 shares in the company, valued at approximately $371,898.54. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Briggs Morrison sold 62,292 shares of the stock in a transaction on Friday, July 1st. The shares were sold at an average price of $19.00, for a total transaction of $1,183,548.00. Following the transaction, the insider now owns 17,836 shares in the company, valued at $338,884. The disclosure for this sale can be found here. In the last three months, insiders sold 93,994 shares of company stock valued at $1,851,186. Corporate insiders own 6.30% of the company's stock.